Chromosome 22q11.2 Deletion Syndrome: Comparison
View Latest Version
Please note this is a comparison between Version 2 by Jessie Wu and Version 1 by Paulina Ostrowska.

The chromosome 22q11.2 (22q11.2) deletion syndrome is a multisystemic disorder characterized by a marked variability of phenotypic features, making the diagnosis challenging for clinicians. The wide spectrum of clinical manifestations includes congenital heart defects—most frequently conotruncal cardiac anomalies—thymic hypoplasia and predominating cellular immune deficiency, laryngeal developmental defects, midline anomalies with cleft palate and velar insufficiency, structural airway defects, facial dysmorphism, parathyroid and thyroid gland hormonal dysfunctions, speech delay, developmental delay, and neurocognitive and psychiatric disorders. 

  • 22q11.2 deletion
  • microdeletion
  • DiGeorge syndrome
  • velocardiofacial syndrome
  • dysmorphism
  • inborn errors of immunity
  • thymus

1. Introduction

The chromosome 22q11.2 deletion syndrome (22q11.2 DS), also known as DiGeorge syndrome (DGS) or velocardiofacial syndrome (VCFS), is a genetic condition resulting from the impaired development of structures originating from the third and fourth pharyngeal pouches in the germinal stage. The clinical features of the syndrome include hypoparathyroidism and hypocalcemia, thymic hypoplasia, conotruncal heart defects, facial dysmorphism, and palatoschisis. The complex phenotype of children affected with 22q11.2 DS may show considerable intersubject variability, and the expanded clinical manifestations comprise craniofacial, neurological, cognitive, behavioral, ocular, speech and hearing, musculoskeletal, and internal organs, as well as airway, gastrointestinal or renal abnormalities [1]. The phenotypes may vary considerably among patients with immunodeficiency and immune dysregulation, including autoimmunity, allergy, and lymphoproliferative sequelae.
The incidence of 22q11.2 DS has been estimated to range from 1:3000 [2] to 1:4000 live births [1], placing it among frequent syndromic diseases. However, the rate of its clinical suspicion is still challenging, and the process of establishing the definitive diagnosis is an odyssey [3] due to the remarkable heterogeneity of clinical phenotypic expressions and overlapping manifestations with other categories of syndromic disorders [4,5,6][4][5][6]. The disease entities, such as, but not limited to, coloboma-heart defects-choanal atresia-retardation of growth and development-ear anomalies (CHARGE) syndrome [7[7][8],8], cardio-facio-cutaneous (CFC) syndrome [9[9][10],10], and Takenouchi-Kosaki syndrome (TKS) [11[11][12],12], require special pediatrician awareness and multidisciplinary care, as their distinctive phenotypes are associated with immunodeficiencies. Furthermore, a common denominator of 22q11.2 DS and other syndromic disorders is an increased susceptibility to recurrent infections, which may not result only from inborn errors of immunity; a multiplicity of developmental anatomical malformations and organ dysfunctions are also important contributing factors. These extra-immune phenotypes in 22q11.2 DS, with neurological, psychomotor, hormonal, circulatory, and respiratory pathophysiological mechanisms, are substantially underpinning the definitive clinical manifestations.

2. Immune Deficiency and Immune Dysregulation

Immunodeficiency is a key feature of 22q11.2 DS and is secondary to thymic aplasia or hypoplasia with subsequent impaired thymocyte development. The third and fourth pharyngeal pouches are a common embryonic precursor for the thymus, parathyroid glands, and conotruncal regions of the heart. In 22q11.2 DS, maldevelopment of these organs is due to impaired migration of the neural crest cell into pouch ectoderm [85][13]. In the setting of abnormal thymic migration, but with the preservation of residual microscopic nests of thymic epithelial cells, mild to moderate reductions in T cell numbers accompanied by only a mild deficit in T cell function occur in most affected children. However, even in these patients, the T-cell thymic output of recent thymic emigrants, assessed by T-cell receptor excision circles (TRECs) analysis, is very low and decreases with age [86,87][14][15]. Full thymic aplasia appears occasionally, in approximately 1% of cases with 22q11.2 DS [86,88][14][16]. Interestingly, beyond the TBX1 hemizygosity, other genes, such as CRKL in the affected 22q11.2 region, may also have a gene dosing, modifying effect on the phenotypic expression of the syndrome. CRKL is expressed in neural crest-derived tissues and involves thymic development. The effect of compound heterozygosity for TBX1 and CRKL deletion on clinical features and thymus development is additive [89][17].
Consequently, a wide spectrum of T-cell alterations is seen in 22q11.2 DS, ranging from near normal to near completely immunodeficient. Mild T cell immunodeficiency may be found in children with apparently hypoplastic thymus because ectopic retropharyngeal thymic tissue may be preserved [90,91][18][19]. Furthermore, dynamic changes in immunodeficiency are observable over time, and the direct effect of thymic hypoplasia on T cell counts is most apparent in early infancy [86,87][14][15]. They tend to normalize by adulthood in most patients, due to the increased secretion of interleukin (IL)-7 that stimulates the thymic output and peripheral proliferation of T cells [92][20]. The most common deficits include low total CD3+ T cell percentage and absolute count, as well as low numbers of naive CD4+ T helper and CD8+ T cytotoxic/suppressor cells. The naive T cell compartment shows a progressive decline with patients’ age, leading to a predominantly memory phenotype of T cells at the periphery [93][21].
Referring to anatomical maldevelopment and dysfunction in generating T cells, the humoral immunodeficiency and B cell abnormalities in children with 22q11.2 DS are secondary to T cell deficits [94][22]. Low immunoglobulin production, most frequently affecting IgM and occasionally IgG and rendering the need for immunoglobulin replacement therapy, as well as the defective immune response to polysaccharide antigens, have been reported in children with the syndrome [95][23]. Among the B cell subsets, low switched memory B cells expanding by adulthood, accompanied by decreased somatic hypermutation despite increased follicular T helper cells, have been shown, reflecting a dysregulated B cell compartment and compromised T cell help [96,97,98][24][25][26]. Recurrent respiratory infections, such as adenotonsillitis, otitis media, bronchitis, pneumonia, as well as sepsis [99,100][27][28], also occur.
Immune dysregulation in 22q11.2 DS has been foremostly ascribed to T-cell lymphopenia and deficiency in CD3+CD4+CD25++, FOXP3+ regulatory T cells, which play a crucial role in maintaining immune homeostasis and self-tolerance. Reduced thymic output related to an increased naive T cell subset, and subsequent T regulatory cell activation, control the expansion of the T cell compartment. A reduced number of regulatory T cells, with their activated phenotype and loss of suppressive capacity in children with 22q11.2 DS, are key features of deregulated T cell homeostasis [101][29]. Beyond the T cell compartment, immunophenotype anomalies also encompass peculiar B cell developmental disorders with increased naive B cells and deficit in switched memory B cells [102][30] which are biomarkers of immune dysregulation in 22q11.2 DS. It has been postulated that the individual patient’s immunophenotype may be influenced by genetic modifiers outside the microdeletion locus which regulatethe expression of TBX1. Rare DNA variants in transcriptional regulators involved in retinoic acid signaling, NCOR2 and EP300, were found to be associated with parameters of the immune functions, such as immunoglobulin levels, lymphocyte response to antigens and mitogens, and flow cytometric lymphocyte compartment. Retinoic acid plays an important role in maintaining immune homeostasis by enhancing the differentiation of regulatory T cells, modulating epithelial and mucosal immune responses, and regulating proinflammatory cytokine activity. Hence, genetic modifiers contributing to the individual’s genetic background and modulating variable penetrance may influence the immune response in 22q11.2 DS [103,104][31][32].
Autoimmune disorders have been described in as many as 23% of pediatric patients with the syndrome [105][33], manifesting as autoimmune thyroid disease, juvenile idiopathic arthritis, autoimmune cytopenia (thrombocytopenia, hemolytic anemia, neutropenia), celiac disease, psoriasis, vitiligo, autoimmune hepatitis, and inflammatory bowel disease [100,105,106,107][28][33][34][35]. It has also been hypothesized that psychotic disorders, developmental regression, and cognitive impairment in children with 22q11.2 DS may have a causal relationship with autoimmune encephalitis [108][36].
The peripheral homeostatic expansion of T cells driven by low thymic output and T cell lymphopenia may contribute to Th2-skewed lymphocyte phenotype and atopic manifestations, such as eczema and asthma [109][37]. In these children with 22q.11.2 DS, the overall frequency of atopic diseases has been estimated to reach 70% and the frequency of asthma to as many as 50% [110][38]. Coexisting gastroesophageal reflux and sinopulmonary infections may have an impact on its clinical course [111][39].
The thymus dysfunction and immunophenotypic abnormalities within the T cell compartments in 22q11.2 DS make affected children susceptible to cancerogenic viruses, such as Epstein-Barr virus (EBV) and human papilloma virus (HPV), that might be linked to an increased risk of malignant transformation. It has also been postulated that chronic immune activation of peripherally expanded T cell population in dysfunctional cellular immunity may underpin the predisposition to developing lymphoproliferative disorders and lymphomagenesis [112][40], as T cell and B cell lymphomas [113[41][42][43],114,115], as well as acute lymphoblastic leukemia [116][44], have been reported in children with 22q11.2 DS. The spectrum of malignancies in affected pediatric patients also includes solid tumors—namely Wilms tumor—hepatoblastoma, neuroblastoma, thyroid carcinoma [116][44], pineoblastoma [112][40], and xanthoastrocytoma [117][45].

3. Diagnosis

The chromosomal 22q11.2 DS is a clinically highly variable microdeletion syndrome with differently expressed phenotypes, with wide interfamilial and intrafamilial variability in patients sharing the same genetic underpinnings [118][46]. This is due to both the remarkable complexity of the 22q11.2 region with LCR blocks and the high susceptibility of this region to meiotic errors, as well as the epigenomic and environmental factors influencing the phenotypic variability [119][47]. Based on functional genomic assessments, it has also been hypothesized that theories on single-gene haploinsufficiency in 22q11.2 DS cannot be supported. In the setting of diminished 22q11.2 gene dosage, shared molecular functions, convergence on cellular processes, and related consequences on the genetic level point to the matrix or multigenic interactions that translate into the multiplicity of phenotypes [120][48]. All these genetic factors, together with age-related developing symptomatology, contribute to diagnostic challenges in 22q11.2 DS pediatric patients on the diverse individual, family, social, and population levels. The summary of modifying variants influencing the TBX1 penetrance and related phenotypic expression is shown in Table 1 [17,18,19,52,53,103,104,118,120,121,122,123,124][31][32][46][48][49][50][51][52][53][54][55][56][57].
Table 1.
Genetic modifiers influencing the
TBX1
penetrance and affecting the phenotypic expression in 22q11.2 DS.
Genetic Modifier Role Phenotypic Expression
CRKL

(CRK like proto-oncogene adaptor protein)		 Activates the RAS and JUN kinase signaling pathways, mediates transduction of intracellular signals Development of organs originating from the neural crest, thymus, parathyroid glands, craniofacial structures, T lymphocytes, cardiac outflow region
SLC2A3 aka GLUT3

(Solute carrier family 2 member 3)		 Facilitated glucose transporter Conotruncal heart region, aortic arch
KANSL1

(KAT8 regulatory NSL complex subunit 1)		 Histone acetyltransferase complex member Developmment of aortic arch, semilunar valve, cardiac septa, pulmonary artery
JMJD1C

(jumonji domain containing 1C)		 Chromatin expression modification, histone demethylation Pharyngeal apparatus, cardiac outflow region
RREB1

(Ras responsive element binding protein 1)		 Chromatin expression modification, histone demethylation Conotruncal heart region
SEC24C

(SEC24 family member C)		 Role in transporting proteins from the endoplasmic reticulum to the Golgi apparatus Embryonic development, cardiac outflow region
MINA

(MYC induced nuclear antigen)		 Chromatin expression modification, histone demethylation Cardiac development
KDM7A

(Lysine-specific demethylase 7A)		 Chromatin expression modification, histone demethylation Cardiac development
DGCR8

(DiGeorge syndrome critical region 8)		 miRNAs and lnRNAs regulation Embryo development, Immune, naurological, and cardiac functions
NCOR2

(Nuclear receptor corepressor 2)		 Transcriptional regulator of the retinoic acid signaling B and T lymphocytes, regulation of the immune response
EP300

(E1A binding protein P300)		 Transcriptional regulator of the retinoic acid signaling B and T lymphocytes, regulation of the immune response
The diagnosis of 22q11.2 DS has been traditionally based on the recognition of clinical features and cytogenetic testing using the fluorescence in situ hybridization (FISH) technique. FISH is perceived as the golden standard genetic testing method to confirm the diagnosis of microdeletion syndromes. However, poor clinical accuracy, the low confirmatory rate in the screening of suspected microdeletion syndromes, and failure to detect other than the targeted microdeletion are the major drawbacks of this method. An important limitation of this method is a failure to identify atypical and nested deletions because it can recognize deletions in the proximal part of the critical region, including the typical LCR22A-D deletion. FISH is admittedly inexpensive, yet still a highly labor-intensive and time-consuming procedure [125][58]. Importantly, due to a marked clinical variability from minimal to full manifestation in patients with 22q11.2 DS, precision in defining clinical criteria is important for referring patients to undergo FISH analysis. Since FISH alone cannot provide a reliable diagnosis of 22q11.2 DS, other diagnostic methods have been developed, such as comparative genomic hybridization (CGH), multiplex ligation-dependent probe amplification (MLPA), multiplex quantitative real-time polymerase chain reaction (qPCR), and high-resolution single-nucleotide polymorphism (SNP) microarray analysis [126][59]. Although the FISH method is still routinely used in laboratories, the MLPA assay has been perceived as an alternative that is superior to the FISH technique as it is less costly, less time-consuming, and laborious, and does not require cell cultures. It has been proposed that a locus-specific approach, using FISH or MLPA assays, could be offered to children strongly meeting clinical and dysmorphology criteria for 22q11.2 DS [126,127][59][60]. Even though FISH is a state-of-the-art procedure for patients with the clinical suspicion of 22q11.2 DS, at present, patients are usually diagnosed by indirect whole genome studies [128][61]. Referring to the regulatory role of the TBX1 gene during development of the heart, thymus, and parathyroid glands, as well as during formation of the palate, teeth, and craniofacial features, there has been growing evidence that TBX1 is a candidate gene for 22q11.2 DS [129,130][62][63]. Therefore, in patients with clinically evident disease in whom a deletion of 22q11.2 has not been identified by FISH or microarray tests, TBX1 gene testing is recommended. Genotype first approach has therefore been proposed, and whole genome sequencing as the first-line method in the not-too-distant future, with FISH to be used as a confirmation of patient and family screening results [125][58].
Newborn screening (NBS) for severe combined immunodeficiency (SCID) is identifying a subset of infants with 22q11.2 DS due to T cell lymphopenia and low TREC numbers, and, hence, it is not a universally reliable detecting method. Therefore, direct NBS for 22q11.2 DS to recognize affected neonates using the genomic approach with multiplex qPCR assay, targeted to the TBX1 gene within the LCR22A-B region and CRKL within the LCR22C-D region, has been elaborated [131][64].
Whereas postnatal phenotypes have been widely characterized and categorized, prenatal diagnosis of 22q11.2 DS remains challenging due to a low rate of inheritance (10% of cases) and mild unrecognized parental features. Fetal ultrasound imaging may provide information on findings characteristic for 22q11.2 DS, such as polyhydramnios, hypoplasia or aplasia of the fetal thymus, central nervous system anomalies, such as asymmetric ventriculomegaly and dilated cavum septum pellucidum, and, rarely, skeletal anomalies, among others, such as bilateral talipes and anomalous vertebrae [132][65].
The golden standard method for detecting 22q11.2 microdeletions remains first trimester screening by chromosomal microarray (CMA), which is performed in invasively obtained prenatal samples, such as chorionic villi and amniotic fluid. An important technical advance in prenatal noninvasive screening for 22q11.2 is cell-free DNA testing [133][66]. Cell-free DNA fragments present in maternal plasma, which derive from both the mother and the embryo as a result of apoptosis of the cytotrophoblast. An external layer of the placenta is used for qualitative and quantitative assays. The fetal fraction is screened for common trisomy and 22q11.2 deletion, as well as for other rare trisomies and microdeletions. Targeted technologies, such as single-nucleotide polymorphism (SNP)-based, digital analysis of selected regions (DANSR), and targeted capture enrichment assay (TCEA) technologies, as well as the genome-wide methodology massively parallel shotgun sequencing (MPSS), are advanced techniques used in cell-free DNA analysis [133,134,135,136,137][66][67][68][69][70].

4. Therapeutic Approach

The marked phenotypic variability of 22q11.2 DS is accompanied by a wide scope of immune deficits, ranging from mild to moderate T cell lymphopenia in the partial form of DiGeorge syndrome (pDGS) to profound combined T and B cell immunodeficiency in the complete form (cDGS). In the first case, hypoplastic ectopic thymus or microscopic thymic rests are found and successful spontaneous immunocorrection has been reported, whereas the latter case is characterized by complete athymia [138][71]. In those most severely immunocompromised children, immune reconstitution may be achieved by thymus transplantation, providing the ability to produce naive T cells showing a broad T cell receptor repertoire. To facilitate the optimal establishment of thymic allograft, stability of comorbidities, such as attaining cardiopulmonary function, upper airway stabilization, appropriate weight gain, and metabolic compensation, are essential to avoid graft failure. The management of concurrent disorders plays a fundamental role in the timing of thymus transplantation, which requires optimal planning and sequencing [139][72]. Another approach to cDGS is T cell-replete hematopoietic stem cell transplantation; however, due to the absence of the thymus, engraftment of post-thymic T cells may result in poor quality of immune reconstitution [94,140,141][22][73][74]. Although 22q11.2 DS has been perceived as a T cell deficiency, disorders of B cell maturation and reduced numbers and functions in naive, unswitched, and switched memory B cells have also been reported. Humoral immunodeficiency in children with 22q11.2 DS may considerably vary from hypogammaglobulinemia with low all immunoglobulin isotypes and the need to receive immunoglobulin replacement therapy (approximately 6% and 3% of them, respectively) [95][23] to low serum IgA or IgM and impaired antigen-specific vaccine response in sporadic cases [142,143][75][76]. Despite the vast majority of children with 22q11.2 DS having normal serum immunoglobulin levels, due to the variable degree of cellular immunity impairment, they are susceptible to acute and recurrent infections, among others such as sinusitis, otitis media, mastoiditis, pneumonia, urinary tract infections, and viral infections [144,145][77][78]. Important questions are then raised about indications for preventive measures against infections in those children who do not qualify for immunoglobulin replacement therapy but present with T-cell lymphopenia. Antibiotic prophylaxis is indicated for children with 22q11.2 DS, first of all in those with low IgA serum levels and panhypogammaglobulinemia presenting with recurrent respiratory tract infections during epidemic season. The prophylactic regimens include daily or alternate-daily use of amoxicillin or azithromycin and co-trimoxazole in children with advanced T-cell lymphopenia posing the risk of Pneumocystis jiroveci infection [136,146,147][69][79][80].
Active immunization in children with 22q11.2 DS requires optimizing to provide vaccination coverage against vaccine-preventable infections. Live vaccine practices with Bacille Calmette-Guerin (BCG), and vaccines against measles-mumps-rubella (MMR), varicella (VAR), and an intranasal live attenuated influenza vaccine (LAIV), are contraindicated in children with this syndrome as T cell lymphopenia makes them susceptible to adverse effects following live immunization (AEFLI). Furthermore, in those children who, due to hypogammaglobulinemia, receive immunoglobulin replacement therapy either intravenously or subcutaneously, live vaccines are inactivated by administered antibodies and thereby are contraindicated. Inactivated vaccines can be safely administered to immunodeficient patients as they do not pose the risk of an uncontrolled spreading of vaccine microorganisms in the patient’s body, and they are not inactivated by supplemented immunoglobulins. However, the immune response to vaccines with antigen-specific antibodies and memory B cell generation may be significantly reduced [148][81].
However, many individuals with 22q11.2 DS with mild to moderate immunosuppression receive live viral MMR and varicella vaccines despite the known diagnosis and tolerate them well, without serious adverse effects [149,150][82][83]. Given the risk of natural infection, the benefits of protection following immunizations with live vaccines outweigh the risks of potential AEFLI. To assess the safety of live attenuated vaccines and evaluate the ability to generate an effective immune response in children with 22q11.2 DS, immunological investigations prior to the administration of live vaccines have been proposed [151][84]. The recommended immunology workup practices include lymphocyte immunophenotyping with the evaluation of total CD3+ T cells, CD4+ T helper cells, CD8+ T cytotoxic cells, and CD3+CD4+CD45RA+CD31+ recent thymic emigrants, as well as response to mitogen phytohemagglutinin (PHA). Live vaccines can be safely administered in children showing a total T cell count above 0.5 × 109/L, a cytotoxic T cell count above 0.2 × 109/L, and a normal response to mitogen [151][84].

References

  1. Cortés-Martín, J.; Peñuela, N.L.; Sánchez-García, J.C.; Montiel-Troya, M.; Díaz-Rodríguez, L.; Rodríguez-Blanque, R. Deletion Syndrome 22q11.2: A Systematic Review. Children 2022, 9, 1168.
  2. Fomin, A.B.; Pastorino, A.C.; Kim, C.A.; Pereira, A.C.; Carneiro-Sampaio, M.; Jacob, C.M.A. DiGeorge Syndrome: A not so rare disease. Clinics 2010, 65, 865–869.
  3. Palmer, L.D.; Butcher, N.J.; Boot, E.; Hodgkinson, K.A.; Heung, T.; Chow, E.W.C.; Guna, A.; Crowley, T.B.; Zackai, E.; McDonald-McGinn, D.M.; et al. Elucidating the diagnostic odyssey of 22q11.2 deletion syndrome. Am. J. Med. Genet. Part A 2018, 176, 936–944.
  4. Kersseboom, R.; Brooks, A.; Weemaes, C. Educational paper: Syndromic forms of primary immunodeficiency. Eur. J. Pediatr. 2011, 170, 295–308.
  5. Bardou, M.L.D.; Henriques, M.T.; Grumach, A.S. Inborn errors of immunity associated with characteristic phenotypes. J. Pediatr. 2021, 97, S75–S83.
  6. Szczawinska-Poplonyk, A.; Begier, K.; Dorota, A.; Dabrowska, M.; Galecka, D.; Wawrzeniak, K.; Wroblewski, K. Syndromic immunodeficiencies: A pediatrician’s perspective on selected diseases. Allergol. Immunopathol. 2020, 49, 117–136.
  7. Hsu, P.; Ma, A.; Wilson, M.; Williams, G.; Curotta, J.; Munns, C.F.; Mehr, S. CHARGE syndrome: A review. J. Paediatr. Child Health 2014, 50, 504–511.
  8. Trider, C.-L.; Arra-Robar, A.; van Ravenswaaij-Arts, C.; Blake, K. Developing a CHARGE syndrome checklist: Health supervision across the lifespan (from head to toe). Am. J. Med. Genet. Part A 2017, 173, 684–691.
  9. Szczawińska-Popłonyk, A.; Popłonyk, N.; Niedziela, M.; Sowińska-Seidler, A.; Sztromwasser, P.; Jamsheer, A.; Obara-Moszyńska, M. Case report: The cardio-facio-cutaneous syndrome due to a novel germline mutation in MAP2K1: A multifaceted disease with immunodeficiency and short stature. Front. Pediatr. 2022, 10, 990111.
  10. Pierpont, M.E.M.; Magoulas, P.L.; Adi, S.; Kavamura, M.I.; Neri, G.; Noonan, J.; Pierpont, E.I.; Reinker, K.; Roberts, A.E.; Shankar, S.; et al. Cardio-Facio-Cutaneous Syndrome: Clinical Features, Diagnosis, and Management Guidelines. Pediatrics 2014, 134, e1149–e1162.
  11. Bucciol, G.; Pillay, B.; Casas-Martin, J.; Delafontaine, S.; Proesmans, M.; Lorent, N.; Coolen, J.; Tousseyn, T.; Bossuyt, X.; Ma, C.S.; et al. Systemic Inflammation and Myelofibrosis in a Patient with Takenouchi-Kosaki Syndrome due to CDC42 Tyr64Cys Mutation. J. Clin. Immunol. 2020, 40, 567–570.
  12. Martinelli, S.; Krumbach, O.H.; Pantaleoni, F.; Coppola, S.; Amin, E.; Pannone, L.; Nouri, K.; Farina, L.; Dvorsky, R.; Lepri, F.; et al. Functional Dysregulation of CDC42 Causes Diverse Developmental Phenotypes. Am. J. Hum. Genet. 2018, 102, 309–320.
  13. Gennery, A.R. Immunological aspects of 22q11.2 deletion syndrome. Cell. Mol. Life Sci. 2012, 69, 17–27.
  14. Dar, N.; Gothelf, D.; Korn, D.; Frisch, A.; Weizman, A.; Michaelovsky, E.; Carmel, M.; Yeshayahu, Y.; Dubnov-Raz, G.; Pessach, I.M.; et al. Thymic and bone marrow output in individuals with 22q11.2 deletion syndrome. Pediatr. Res. 2015, 77, 579–585.
  15. Gul, K.A.; Øverland, T.; Osnes, L.; Baumbusch, L.O.; Pettersen, R.D.; Lima, K.; Abrahamsen, T.G. Neonatal Levels of T-cell Receptor Excision Circles (TREC) in Patients with 22q11.2 Deletion Syndrome and Later Disease Features. J. Clin. Immunol. 2015, 35, 408–415.
  16. Collins, C.; Sharpe, E.; Silber, A.; Kulke, S.; Hsieh, E.W.Y. Congenital Athymia: Genetic Etiologies, Clinical Manifestations, Diagnosis, and Treatment. J. Clin. Immunol. 2021, 41, 881–895.
  17. Guris, D.L.; Duester, G.; Papaioannou, V.; Imamoto, A. Dose-Dependent Interaction of Tbx1 and Crkl and Locally Aberrant RA Signaling in a Model of del22q11 Syndrome. Dev. Cell 2006, 10, 81–92.
  18. Shah, S.S.; Lai, S.Y.; Ruchelli, E.; Kazahaya, K.; Mahboubi, S. Retropharyngeal Aberrant Thymus. Pediatrics 2001, 108, e94.
  19. Grudzień, K.; Kuzaj, J.; Dębicka, M.; Kwiatkowski, S.; Milczarek, O. Retropharyngeal Ectopic Thymus in a Pediatric Patient With 22q11.2 Deletion Syndrome. Cureus 2023, 15, e33350.
  20. Crowley, B.; Ruffner, M.; McGinn, D.M.M.; Sullivan, K.E. Variable immune deficiency related to deletion size in chromosome 22q11.2 deletion syndrome. Am. J. Med. Genet. Part A 2018, 176, 2082–2086.
  21. Giardino, G.; Borzacchiello, C.; De Luca, M.; Romano, R.; Prencipe, R.; Cirillo, E.; Pignata, C. T-Cell Immunodeficiencies with Congenital Alterations of Thymic Development: Genes Implicated and Differential Immunological and Clinical Features. Front. Immunol. 2020, 11, 1837.
  22. Davies, E.G. Immunodeficiency in DiGeorge Syndrome and Options for Treating Cases with Complete Athymia. Front. Immunol. 2013, 4, 322.
  23. Patel, K.; Akhter, J.; Kobrynski, L.; Gathman, B.; Davis, O.; Sullivan, K.E. Immunoglobulin Deficiencies: The B-Lymphocyte Side of DiGeorge Syndrome. J. Pediatr. 2012, 161, 950–953.e1.
  24. Zemble, R.; Prak, E.L.; McDonald, K.; McDonald-McGinn, D.; Zackai, E.; Sullivan, K. Secondary immunologic consequences in chromosome 22q11.2 deletion syndrome (DiGeorge syndrome/velocardiofacial syndrome). Clin. Immunol. 2010, 136, 409–418.
  25. Derfalvi, B.; Maurer, K.; McGinn, D.M.M.; Zackai, E.; Meng, W.; Prak, E.T.L.; Sullivan, K.E. B cell development in chromosome 22q11.2 deletion syndrome. Clin. Immunol. 2016, 163, 1–9.
  26. Montin, D.; Marolda, A.; Licciardi, F.; Robasto, F.; DI Cesare, S.; Ricotti, E.; Ferro, F.; Scaioli, G.; Giancotta, C.; Amodio, D.; et al. Immunophenotype Anomalies Predict the Development of Autoimmune Cytopenia in 22q11.2 Deletion Syndrome. J. Allergy Clin. Immunol. Pract. 2019, 7, 2369–2376.
  27. Wahrmann, S.; Kainulainen, L.; Kytö, V.; Lempainen, J. Childhood manifestations of 22q11.2 deletion syndrome: A Finnish nationwide register-based cohort study. Acta Paediatr. 2023; online.
  28. Di Cesare, S.; Puliafito, P.; Ariganello, P.; Marcovecchio, G.E.; Mandolesi, M.; Capolino, S.; Digilio, M.C.; Aiuti, A.; Rossi, P.; Cancrini, C. Autoimmunity and regulatory T cells in 22q11.2 deletion syndrome patients. Pediatr. Allergy Immunol. 2015, 26, 578–594.
  29. Ferrando-Martínez, S.; Lorente, R.; Gurbindo, D.; De José, M.I.; Leal, M.; Muñoz-Fernández, M.A.; Correa-Rocha, R. Low Thymic Output, Peripheral Homeostasis Deregulation, and Hastened Regulatory T Cells Differentiation in Children with 22q11.2 Deletion Syndrome. J. Pediatr. 2014, 164, 882–889.
  30. Framme, J.L.; Lundqvist, C.; Lundell, A.C.; van Schouwenburg, P.A.; Lemarquis, A.L.; Thörn, K.; Lindgren, S.; Gudmundsdottir, J.; Lundberg, V.; Degerman, S.; et al. Long-term follow-up of newborns with 22q11 deletion syndrome and low TRECs. J. Clin. Immunol. 2022, 42, 618–633.
  31. Pinnaro, C.T.; Henry, T.; Major, H.J.; Parida, M.; DesJardin, L.E.; Manak, J.R.; Darbro, B.W. Candidate modifier genes for immune function in 22q11.2 deletion syndrome. Mol. Genet. Genom. Med. 2019, 8, e1057.
  32. Oliveira, L.D.M.; Teixeira, F.M.E.; Sato, M.N. Impact of Retinoic Acid on Immune Cells and Inflammatory Diseases. Mediat. Inflamm. 2018, 2018, 3067126.
  33. Cancrini, C.; Puliafito, P.; Digilio, M.C.; Soresina, A.; Martino, S.; Rondelli, R.; Consolini, R.; Ruga, E.M.; Cardinale, F.; Finocchi, A.; et al. Clinical Features and Follow-Up in Patients with 22q11.2 Deletion Syndrome. J. Pediatr. 2014, 164, 1475–1480.e2.
  34. Deshpande, D.R.; Demirdag, Y.Y.; Marsh, R.A.; Sullivan, K.E.; Orange, J.S.; The USIDNET Consortium. Relationship between Severity of T Cell Lymphopenia and Immune Dysregulation in Patients with DiGeorge Syndrome (22q11.2 Deletions and/or Related TBX1 Mutations): A USIDNET Study. J. Clin. Immunol. 2021, 41, 29–37.
  35. Mahé, P.; Nagot, N.; Portales, P.; Lozano, C.; Vincent, T.; Sarda, P.; Perez, M.; Amedro, P.; Marin, G.; Jeziorski, E. Risk factors of clinical dysimmune manifestations in a cohort of 86 children with 22q11.2 deletion syndrome: A retrospective study in France. Am. J. Med. Genet. Part A 2019, 179, 2207–2213.
  36. Ciano-Petersen, N.L.; Hamad-Cueto, O.; Drissi-Reyes, H.; Dona-Diaz, A.; Garcia-Martin, G. Case report: Autoimmune psychosis in 22q11.2 deletion syndrome. Front. Immunol. 2021, 12, 708625.
  37. Jesenak, M.; Zelieskova, M.; Repko, M.; Banovcin, P. Successful treatment of severe allergic asthma with omalizumab in a girl with DiGeorge syndrome. Central Eur. J. Immunol. 2020, 45, 361–363.
  38. Morsheimer, M.; Brown Whitehorn, T.F.; Heimall, J.; Sullivan, K.E. The immune deficiency of chromosome 22q11.2 deletion syndrome. Am. J. Med. Genet. Part A 2017, 173, 2366–2372.
  39. Maggadottir, S.M.; Sullivan, K.E. The Diverse Clinical Features of Chromosome 22q11.2 Deletion Syndrome (DiGeorge Syndrome). J. Allergy Clin. Immunol. Pract. 2013, 1, 589–594.
  40. Stevens, T.; Van Der Werff Ten Bosch, J.; De Rademaeker, M.; Van Den Bogaert, A.; Akker, M.V.D. Risk of malignancy in 22q11.2 deletion syndrome. Clin. Case Rep. 2017, 5, 486–490.
  41. Itoh, S.; Ohno, T.; Kakizaki, S.; Ichinohasama, R. Epstein-Barr virus-positive T-cell lymphoma cells having chromosome 22q11.2 deletion: An autopsy report of DiGeorge syndrome. Hum. Patol. 2011, 42, 2037–2041.
  42. Hong, R.; Shen, V.; Rooney, C.; Hughes, D.P.; Smith, C.; Comoli, P.; Zhang, L. Correction od DiGeorge anomaly with EBV-induced lymphoma by transplantation of organ-cultured thymus and Epstein Barr-specific cytotixic T lymphocytes. Clin. Immunol. 2001, 91, 54–61.
  43. Pongpruttipan, T.; Cook, J.R.; Reyes-Mugica, M.; Spahr, E.; Swerdlow, S.H. Pulmonary extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue associated with granulomatous inflammation in a child with chromosome 22q11.2 deletion syndrome (DiGeorge syndrome). J. Pediatr. 2012, 161, 954–958.
  44. McDonald-McGinn, D.M.; Reilly, A.; Wallgren-Pettersson, C.; Hoyme, H.E.; Yang, S.P.; Adam, M.P.; Zackai, E.H.; Sullivan, K.E. Malignancy in chromosome 22q11.2 deletion syndrome (DiGeorge syndrome/velocardiofacial syndrome). Am. J. Med. Genet. Part A 2006, 140, 906–909.
  45. Murray, J.C.; Donahue, D.J.; Malik, S.I.; Dzurik, Y.B.; Braly, E.Z.; Dougherty, M.J.; Eaton, K.W.; Biegel, J.A. Temporal lobe pleomorphic xanthoastrocytoma and acquired BRAF mutation in an adolescent with the constitutional 22q11.2 deletion syndrome. J. Neuro-Oncol. 2011, 102, 509–514.
  46. Digilio, M.C.; Angioni, A.; De Santis, M.; Lombardo, A.; Giannotti, A.; Dallapiccola, B.; Marino, B. Spectrum of clinical variability in familial deletion 22q11.2: From full manifestation to extremely mild clinical anomalies. Clin. Genet. 2003, 63, 308–313.
  47. Karbarz, M. Consequences of 22q11.2 microdeletion on the genome, individual and population level. Genes 2020, 11, 977.
  48. Motahari, Z.; Moody, S.A.; Maynard, T.M.; LaMantia, A.S. In the line-up: Deleted genes associated with DiGeorge/22q11.2 deletion syndrome: Are they all suspects? J. Neurodev. Disord. 2019, 11, 7.
  49. Funato, N. Craniofacial Phenotypes and Genetics of DiGeorge Syndrome. J. Dev. Biol. 2022, 10, 18.
  50. Gao, S.; Moreno, M.; Eliason, S.; Cao, H.; Li, X.; Yu, W.; Bidlack, F.B.; Margolis, H.C.; Baldini, A.; Amendt, B.A. TBX1 protein interactions and microRNA-96-5p regulation controls cell proliferation during craniofacial and dental development: Implications for 22q11.2 deletion syndrome. Hum. Mol. Genet. 2015, 24, 2330–2348.
  51. Du, Q.; De La Morena, M.T.; Van Oers, N.S.C. The Genetics and Epigenetics of 22q11.2 Deletion Syndrome. Front. Genet. 2020, 10, 1365.
  52. Zhao, Y.; Diacou, A.; Johnston, H.R.; Musfee, F.I.; McDonald-McGinn, D.M.; McGinn, D.; Crowley, T.B.; Repetto, G.M.; Swillen, A.; Breckpot, J.; et al. Complete Sequence of the 22q11.2 Allele in 1053 Subjects with 22q11.2 Deletion Syndrome Reveals Modifiers of Conotruncal Heart Defects. Am. J. Hum. Genet. 2020, 106, 26–40.
  53. Mlynarski, E.E.; Xie, M.; Taylor, D.; Sheridan, M.B.; Guo, T.; Racedo, S.E.; McDonald-McGinn, D.M.; Chow, E.W.C.; Vorstman, J.; Swillen, A.; et al. Rare copy number variants and congenital heart defects in the 22q11.2 deletion syndrome. Hum. Genet. 2016, 135, 273–285.
  54. Giacomelli, M.; Kumar, R.; Soresina, A.; Tamassia, N.; Lorenzini, T.; Moratto, D.; Gasperini, S.; Cassatella, M.; Plebani, A.; Lougaris, V.; et al. Reduction of CRKL expression in patients with partial DiGeorege syndrome is associated with impairment of T cell functions. J. Allergy Clin. Immunol. 2016, 138, 229–240.
  55. Guo, T.; Chung, J.H.; Wang, T.; McDonald-McGinn, D.M.; Kates, W.R.; Hawuła, W.; Coleman, K.; Zackai, E.; Emanuel, B.S.; Morrow, B.E. Histone Modifier Genes Alter Conotruncal Heart Phenotypes in 22q11.2 Deletion Syndrome. Am. J. Hum. Genet. 2015, 97, 869–877.
  56. León, L.E.; Benavides, F.; Espinoza, K.; Vial, C.; Alvarez, P.; Palomares, M.; Lay-Son, G.; Miranda, M.; Repetto, G.M. Partial microduplication in the histone acetyltransferase complex member KANSL1 is associated with congenital heart defects in 22q11.2 microdeletion syndrome patients. Sci. Rep. 2017, 7, 1795.
  57. Mlynarski, E.E.; Sheridan, M.B.; Xie, M.; Guo, T.; Racedo, S.E.; McDonald-McGinn, D.M.; Gai, X.; Chow, E.W.; Vorstman, J.; Swillen, A.; et al. Copy-Number Variation of the Glucose Transporter Gene SLC2A3 and Congenital Heart Defects in the 22q11.2 Deletion Syndrome. Am. J. Hum. Genet. 2015, 96, 753–764.
  58. Halder, A.; Jain, M.; Chaudhary, I.; Gupta, N.; Kabra, M. Fluorescence in situ hybridization (FISH) using non-commercial probes in the diagnosis of clically suspected microdeletion syndromes. Indian J. Med. Res. 2013, 138, 135–142.
  59. Maran, S.; Faten, S.A.; Lim, S.H.E.; Lai, K.S.; Ibrahim, W.P.W.; Ankathil, R.; Gan, S.H.; Tan, H.L. Screening of 22q11.2 DS using multiplex ligation as alternative diagnostic method. Biomed. Res. Int. 2020, 2020, 6945730.
  60. Monteiro, F.; Vieira, T.P.; Sgardioli, I.C.; Molck, M.C.; Damiano, A.P.; Souza, J.; Monlleo, I.; Fontes, M.I.B.; Fett-Conte, A.C.; Félix, T.M.; et al. Defining new guidelines for screening the 22q11.2 deletion based on a clinical and dysmorphologic evaluation of 194 individuals and review of the literature. Eur. J. Pediatr. 2013, 172, 927–945.
  61. Koczkowska, M.; Wierzba, J.; Śmigiel, R.; Sąsiadek, M.; Cabała, M.; Ślężak, R.; Iliszko, M.; Kardaś, I.; Limon, J.; Lipska-Ziętkiewicz, B.S. Genomic findings in patients with clinical suspicion of 22q11.2 deletion syndrome. J. Appl. Genet. 2017, 58, 93–98.
  62. Gao, S.; Li, X.; Amendt, B.A. Understanding the Role of Tbx1 as a Candidate Gene for 22q11.2 Deletion Syndrome. Curr. Allergy Asthma Rep. 2013, 13, 613–621.
  63. Yagi, H.; Furutani, Y.; Hamada, H.; Sasaki, T.; Asakawa, S.; Minoshima, S.; Ichida, F.; Joo, K.; Kimura, M.; Imamura, S.-I.; et al. Role of TBX1 in human del22q11.2 syndrome. Lancet 2003, 362, 1366–1373.
  64. Barry, J.C.; Crowley, T.B.; Jyonouchi, S.; Heimall, J.; Zackai, E.H.; Sullivan, K.E.; McDonald-McGinn, D.M. Identification of 22q11.2 Deletion Syndrome via Newborn Screening for Severe Combined Immunodeficiency. J. Clin. Immunol. 2017, 37, 476–485.
  65. Schindewolf, E.; Khalek, N.; Johnson, M.P.; Gebb, J.; Coleman, B.; Crowley, T.B.; Zackai, E.H.; McDonald-McGinn, N.M.; Moldenhauer, J.S. Expanding the fetal phenotype: Prenatal sonographic findings and perinatal outcomes in a cohort of patients with a confirmed 22q11.2 deletion syndrome. Am. J. Med. Genet. Part A 2018, 176, 1735–1741.
  66. Grati, F.R.; Gross, S.J. Noninvasive screening by cell-free DNA for 22q11.2 deletion: Benefits, limitations, and challenges. Prenat. Diagn. 2019, 39, 70–80.
  67. Bevilacqua, E.; Jani, C.C.; Chaoui, R.; Suk, E.K.A.; Palma-Dias, R.; Ko, T.M.; Warsof, S.; Stokowski, R.; Jones, K.J.; Grati, F.R.; et al. Performance of targeted cell-free DNA prenatal test for 22q11.2 deletion in a large clinical cohort. Ultrasound Obstet. Gynecol. 2021, 58, 597–602.
  68. Dar, P.; Jacobsson, B.; Clifton, R.; Egbert, M.; Malone, F.; Wapner, R.J.; Roman, A.S.; Khalil, A.; Faro, R.; Madankumar, R.; et al. Cell-free DNA screening for prenatal detection of 22q11.2 deletion syndrome. Am. J. Obstet. Gynecol. 2022, 227, 79.e1–79.e11.
  69. Kagan, K.O.; Hoopmann, M.; Pfaff, T.; Prodan, N.; Wagner, P.; Schmid, M.; Dufke, A.; Mau-Holzmann, U.; Brucker, S.; Marcato, L.; et al. First Trimester Screening for Common Trisomies and Microdeletion 22q11.2 Syndrome Using Cell-Free DNA: A Prospective Clinical Study. Fetal Diagn. Ther. 2020, 47, 841–852.
  70. Blagowidow, N.; Nowakowska, B.; Schindewolf, E.; Grati, F.R.; Putotto, C.; Breckpot, J.; Swillen, A.; Crowley, T.B.; Loo, J.C.Y.; Lairson, L.A.; et al. Prenatal Screening and Diagnostic Considerations for 22q11.2 Microdeletions. Genes 2023, 14, 160.
  71. Biggs, S.E.; Gilchrist, B.; May, K.R. Chromosome 22q11.2 Deletion (DiGeorge Syndrome): Immunologic Features, Diagnosis, and Management. Curr. Allergy Asthma Rep. 2023, 23, 213–222.
  72. Howley, E.; Davies, E.G.; Kreins, A.Y. Congenital athtmia: Unmet needs and practical guidance. Ther. Clin. Risk Manag. 2023, 19, 239–254.
  73. Kreins, A.Y.; Bonfanti, P.; Davies, E.G. Current and future therapeutic approaches for thymic stomal cell defects. Front. Immunol. 2021, 12, 655354.
  74. Davies, E.G.; Cheung, M.; Gilmour, K.; Maimaris, J.; Curry, J.; Furmanski, A.; Sebire, N.; Halliday, N.; Mengrelis, K.; Adams, S.; et al. Thymus transplantation for complete DiGeorge syndrome: European experience. J. Allergy Clin. Immunol. 2017, 140, 1660–1670.e16.
  75. Caka, C.; Cimen, O.; Kahyaoglu Tezcan, I.; Cagdas, D. Selective IgM deficiency: Follow-up and outcome. Pediatr. Allergy Immunol. 2021, 32, 1327–1334.
  76. Kung, S.-J.; Gripp, K.W.; Stephan, M.J.; Fairchok, M.P.; McGeady, S.J. Selective IgM deficiency and 22q11.2 deletion syndrome. Ann. Allergy Asthma Immunol. 2007, 99, 87–92.
  77. Ozen, S.; Akcal, O.; Taskirdi, I.; Haci, I.A.; Karaca, N.E.; Gulez, N.; Aksu, G.; Genel, F.; Kutukculer, N. 22q11.2 deletion syndrome: 20 years of experience from two pediatric immunology units and review of clues for diagnosis and disease management. Allergol. Immunopathol. 2021, 49, 95–100.
  78. Nissan, E.; Katz, U.; Levy-Shraga, Y.; Frizinsky, S.; Carmel, E.; Gothelf, D.; Somech, R. Clinical Features in a Large Cohort of Patients With 22q11.2 Deletion Syndrome. J. Pediatr. 2021, 238, 215–220.e5.
  79. Habel, A.; Herriot, R.; Kumararatne, D.; Allgrove, J.; Baker, K.; Baxendale, H.; Bu’lock, F.; Firth, H.; Gennery, A.; Holland, A.; et al. Towards a safety net for management of 22q11.2 deletion syndrome: Guidelines for our times. Eur. J. Pediatr. 2014, 173, 757–765.
  80. Kuruvilla, M.; de la Morena, M.T. Antibiotic prophylaxis in primary immune deficiency disorders. J. Allergy Clin. Immunol. Pract. 2013, 1, 573–582.
  81. Szczawinska-Poplonyk, A.; Breborowicz, A.; Samara, H.; Ossowska, L.; Dworacki, G. Impaired Antigen-Specific Immune Response to Vaccines in Children with Antibody Production Defects. Clin. Vaccine Immunol. 2015, 22, 875–882.
  82. Hofstetter, A.M.; Jakob, K.; Klein, N.P.; Dekker, C.L.; Edwards, K.M.; Halsey, N.A.; Baxter, R.; Williams, S.E.; Graham, P.L.; LaRussa, P. Live Vaccine Use and Safety in DiGeorge Syndrome. Pediatrics 2014, 133, e946–e954.
  83. Lim, S.M.; Shin, J.H.; Baek, J.Y.; Lee, J.Y.; Kang, J.-M.; Ahn, J.G. Safety of Live Immunization in DiGeorge Syndrome: A Retrospective Single-Center Study in Korea, 2005–2021. Vaccines 2022, 10, 2165.
  84. Berkhout, A.; Preece, K.; Varghese, V.; Prasad, V.; Heussler, H.; Clark, J.; Wen, S.C.H. Optimising immunisation in children with 22q11 microdeletion. Ther. Adv. Vaccines Immunother. 2020, 8, 1–7.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/)
Video Production Service
Feedback